Application/Control Number: 10/569,076 Page 2

Art Unit: 1647

Proposed allowable claims for 10/569,076 as suggested by Examiner Allen 6/24/09 and provided to applicant at interview.

- 1. A fusion polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 4, 6, 7, and 8.
- 2. A fusion polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 4, 6, 7, and 8.
- 3. A nucleic acid comprising a nucleotide sequence encoding the fusion polypeptide of claim 1 or 2.
- 4. A nucleic acid consisting of a nucleotide sequence encoding the fusion polypeptide of claim 1 or 2.
- 5. A nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 10, 11, 13, 14, and 15.
- 6. A nucleic acid consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 10, 11, 13, 14, and 15.
- 7. A vector comprising the nucleic acid of claim 3.
- 8. A vector comprising the nucleic acid of claim 5 or 6.
- 9. An isolated host cell comprising the nucleic acid of claim 3.
- 10. An isolated host cell comprising the vector of claim 7.
- 11. An isolated host cell comprising the vector of claim 8.
- 12. A composition comprising the fusion polypeptide of claim 1 or 2 and a pharmaceutically acceptable carrier, excipient, or adjuvant.
- 13. A composition comprising the nucleic acid of claim 3 and a pharmaceutically acceptable carrier, excipient, or adjuvant.
- 14. A composition comprising the nucleic acid of claim 5 and a pharmaceutically acceptable carrier, excipient, or adjuvant.
- 15. A composition comprising the vector of claim 10 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

Application/Control Number: 10/569,076

Art Unit: 1647

16. A composition comprising the host cell of claim 7 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

Page 3

- 17. A method of treating a patient with a neoplastic disease comprising administering to said patient a fusion polypeptide of SEQ ID NO: 3 or 4 in an amount effective to inhibit tumor growth.
- 18. A method of treating a patient with a neoplastic disease comprising administering to said patient a fusion polypeptide of SEQ ID NO: 3 or 4 in an amount effective to reduce the size of the tumors in the patient.
- 19. A method of treating a patient with a neoplastic disease comprising administering to said patient a composition comprising the fusion polypeptide of SEQ ID NO: 3 or 4 and a pharmaceutically acceptable carrier, excipient, or adjuvant in an amount effective to inhibit tumor growth.
- 20. A method of treating a patient with a neoplastic disease comprising administering to said patient a composition comprising the fusion polypeptide of SEQ ID NO: 3 or 4 and a pharmaceutically acceptable carrier, excipient, or adjuvant in an amount effective to reduce the size of the tumors in the patient.
- 21. The method according to claim 17, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.
- 22. The method according to claim 18, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.
- 23. The method according to claim 19, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.
- 24. The method according to claim 20, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.